Table 1.

Clinical characteristics of patients with ADPKD and matched healthy controls

CharacteristicsADPKDHealthy Controls
NN
Women, n (%)15088 (59)15080 (53)
Age, yr15046±1215046±11
Weight, kg15083±1815081±13
Height, cm150176±10150176±9
Body mass index, kg/m215026.6±4.815026.2±3.2
Systolic BP, mm Hg149127±13150123±11
Diastolic BP, mm Hg14978±915074±8
Antihypertensive use, n (%)150114 (76)15012 (8)
RAAS inhibitor use, n (%)150104 (69)1502 (1)
Protein intake, g/24 h14786±2314190±29
Sodium intake, mmol/24 h147157±60142193±76
eGFR, ml/min per 1.73 m215063±3115092±15
CKD stage, n (%)15027
 127 (18)
 252 (35)
 3A22 (15)
 3B23 (15)
 423 (15)
 53 (2)
htTKV, ml/m143785 (489–1282)
Mayo htTKV class, n (%)143
 1A9 (6)
 1B31 (21)
 1C50 (33)
 1D30 (20)
 1E16 (11)
 27 (5)
PKD mutation, n (%)130
PKD1 truncating53 (35)
PKD1 nontruncating44 (29)
PKD227 (18)
 No mutation detected6 (4)
  • Variables are presented as mean±SD, or as median (interquartile range) in case of non-normal distribution. ADPKD, autosomal dominant polycystic kidney disease; RAAS, renin-angiotensin-aldosterone system; —, not applicable; htTKV, height-adjusted total kidney volume; PKD, polycystic kidney disease.